Genprex Touts Encouraging Preclinical Data From Lung Cancer Candidate

 

• Genprex Inc 
  GNPX+4.89%+ Free Alerts
   announced that its research collaborators presented preclinical data for the NPRL2 gene (also known as the TUSC4 gene). 
• The studies used the company's non-viral Oncoprex Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (NSCLC) humanized mouse models.
• Data were presented at the 2023 American Association of Cancer Research (AACR) annual meeting.
• In the study, humanized mice were treated with NPRL2 gene therapy, immunotherapy Merck's 
  MRK-0.68%+ Free Alerts
   pembrolizumab (Keytruda), or the combination. 
• An antitumor effect was mediated by NPRL2 treatment, whereas pembrolizumab was ineffective. 
• A significant antitumor effect was also found in non-humanized NSG mice. However, the antitumor effect was greater in humanized mice, suggesting that the immune response played a role in inducing antitumor activity.
• The study data suggest that NPRL2 gene therapy induces antitumor activity on KRAS/STK11 mutant anti-PD1 resistant tumors through DC-mediated antigen presentation and cytotoxic immune cell activation.

https://www.benzinga.com/general/biotech/23/04/31892756/genprex-touts-encouraging-preclinical-data-from-lung-cancer-candidate